<DOC>
	<DOCNO>NCT02944565</DOCNO>
	<brief_summary>This phase II trial study side effect well daratumumab work treat patient multiple myeloma infusion accelerate . Monoclonal antibody , daratumumab , may interfere ability tumor cell grow spread .</brief_summary>
	<brief_title>Daratumumab Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine safety tolerability decrease infusion time daratumumab patient already receive 2+ dos daratumumab continue daratumumab . II . Estimate time saving versus ( v ) predict infusion time . OUTLINE : Patients receive daratumumab intravenously ( IV ) 1.5 hour . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must receive &gt; = 2 daratumumab infusion schedule receive another dose All race ethnic group eligible study Ability understand willingness sign write informed consent document Any medical condition , include mental illness substance abuse , deem principal investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result Concurrent use complementary alternative medicine opinion principal investigator would confound interpretation toxicity and/or antitumor activity study drug Prisoner</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>